A Phase 2 interventional study of Dalbavancin and Comparator in Osteomyelitis, sponsored by Durata Therapeutics Inc., an affiliate of Allergan plc. Completed at 1 site in Ukraine. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-04.
Sponsored by Durata Therapeutics Inc., an affiliate of Allergan plc (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This clinical study will be a single-center, randomized, open-label, active-controlled, parallel-group study comparing dalbavancin to standard of care (SOC) therapy in osteomyelitis.
105 studies on the registry are indexed under Osteomyelitis; 30 are open to participants now.
This study's enrollment of 80 is close to the median of 74 across 60 interventional studies indexed under Osteomyelitis.
Browse Osteomyelitis studies →Durata Therapeutics Inc., an affiliate of Allergan plc is the lead sponsor of 6 studies on the registry; none are open to participants now.
First submitted before Durata Therapeutics Inc. became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and Day 8. If creatinine clearance was \< 30 milliliters per minute (mL/min) and participant was not receiving regular hemodialysis or peritoneal dialysis, dalbavancin dose was decreased to 1000 mg.
Drug: Dalbavancin
Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
Drug: Comparator
Also known as: Dalvance®, Xydalba™
Percentage of Participants With Clinical Response at Day 42 in the Clinically Evaluable (CE) Population
Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).
Time frame: Day 42
Percentage of Participants With Clinical Response at Day 365 in the CE Population
Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).
Time frame: Day 365
Percentage of Participants With Clinical Improvement at Day 21 in the mITT Population
Clinical improvement was defined as no worsening of pain from baseline, if present (subjective pain and/or point tenderness), and improvement in inflammation (as measured by C-reactive protein \[CRP\]).
Time frame: Baseline to Day 21
Percentage of Participants With Clinical Improvement at Day 21 in the CE Population
Clinical improvement was defined as no worsening of pain from baseline, if present (subjective pain and/or point tenderness), and improvement in inflammation (as measured by C-reactive protein \[CRP\]).
Time frame: Baseline to Day 21
Percentage of Participants With Clinical Response at Day 42 in the mITT Population
Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).
Time frame: Day 42
Percentage of Participants With Clinical Response at Day 42 in the Microbiological Modified Intent-to-Treat (Micro-mITT) Population
Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).
Time frame: Day 42
Percentage of Participant With Clinical Response at Day 180 in the mITT Population
Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).
Time frame: Day 180
Percentage of Participants With Clinical Response at Day 180 in the CE Population
Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).
Time frame: Day 180
Percentage of Participants With Clinical Response at Day 365 in the mITT Population
Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).
Time frame: Day 365
Number of Participants With Clinical Cure by Baseline Pathogen at Day 42 in the CE Population
Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).
Time frame: Day 42
Number of Participants With Clinical Cure by Baseline Pathogen at Day 180 in the CE Population
Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).
Time frame: Day 180
| Milestone | Dalbavancin | Standard of Care |
|---|---|---|
| Started | 70 | 10 |
| Completed | 67 | 8 |
| Not completed | 3 | 2 |
| Withdrew: Withdrawal of consent | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Adverse event | 1 | 0 |
Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).
| percentage of participants | Dalbavancin | Standard of Care |
|---|---|---|
| Clinical Cure | 97.0 (89.6 to 99.6) | 87.5 (47.3 to 99.7) |
| Clinical Failure | 0.0 (NA to NA) | 12.5 (NA to NA) |
| Indeterminate | 3.0 (NA to NA) | 0.0 (NA to NA) |
Clinical improvement was defined as no worsening of pain from baseline, if present (subjective pain and/or point tenderness), and improvement in inflammation (as measured by C-reactive protein \[CRP\]).
| percentage of participants | Dalbavancin | Standard of Care |
|---|---|---|
| Percentage of Participants With Clinical Improvement at Day 21 in the mITT Population | 94.0 (85.4 to 98.3) | 62.5 (24.5 to 91.5) |
Clinical improvement was defined as no worsening of pain from baseline, if present (subjective pain and/or point tenderness), and improvement in inflammation (as measured by C-reactive protein \[CRP\]).
| percentage of participants | Dalbavancin | Standard of Care |
|---|---|---|
| Percentage of Participants With Clinical Improvement at Day 21 in the CE Population | 94.0 (85.4 to 98.3) | 62.5 (24.5 to 91.5) |
Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).
| percentage of participants | Dalbavancin | Standard of Care |
|---|---|---|
| Clinical Cure | 97.0 (89.6 to 99.6) | 87.5 (47.3 to 99.7) |
| Clinical Failure | 0.0 (NA to NA) | 12.5 (NA to NA) |
| Indeterminate | 3.0 (NA to NA) | 0.0 (NA to NA) |
Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).
| percentage of participants | Dalbavancin | Standard of Care |
|---|---|---|
| Clinical Cure | 96.8 (88.8 to 99.6) | 87.5 (47.3 to 99.7) |
| Clinical Failure | 0.0 (NA to NA) | 12.5 (NA to NA) |
| Indeterminate | 3.2 (NA to NA) | 0.0 (NA to NA) |
Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).
| percentage of participants | Dalbavancin | Standard of Care |
|---|---|---|
| Clinical Cure | 94.0 (85.4 to 98.3) | 87.5 (47.3 to 99.7) |
| Clinical Failure | 3.0 (NA to NA) | 0.0 (NA to NA) |
| Indeterminate | 3.0 (NA to NA) | 12.5 (NA to NA) |
Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).
| percentage of participants | Dalbavancin | Standard of Care |
|---|---|---|
| Clinical Cure | 95.5 (87.3 to 99.1) | 87.5 (47.3 to 99.7) |
| Clinical Failure | 1.5 (NA to NA) | 0.0 (NA to NA) |
| Indeterminate | 3.0 (NA to NA) | 12.5 (NA to NA) |
Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).
| percentage of participants | Dalbavancin | Standard of Care |
|---|---|---|
| Clinical Cure | 94.0 (85.4 to 98.3) | 87.5 (47.3 to 99.7) |
| Clinical Failure | 3.0 (NA to NA) | 0 (NA to NA) |
| Indeterminate | 3.0 (NA to NA) | 12.5 (NA to NA) |
Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).
| percentage of participants | Dalbavancin | Standard of Care |
|---|---|---|
| Clinical Cure | 95.5 (87.3 to 99.1) | 87.5 (47.3 to 99.7) |
| Clinical Failure | 1.5 (NA to NA) | 0 (NA to NA) |
| Indeterminate | 3.0 (NA to NA) | 12.5 (NA to NA) |
Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).
| participants | Dalbavancin | Standard of Care |
|---|---|---|
| Staphylococcus aureus | 41 | 5 |
| Staphylococcus epidermidis | 6 | 2 |
| Staphylococcus haemolyticus | 3 | — |
| Staphylococcus pasteuri | 1 | — |
| Staphylococcus hominis | 1 | — |
| Staphylococcus simulans | 1 | — |
| Enterococcus faecalis | 7 | 1 |
| Enterococcus faecium | 1 | — |
| Streptococcus agalactiae | 1 | 1 |
| Streptococcus dysgalactiae | 1 | — |
| Streptococcus pyogenes | 1 | — |
| Corynebacterium striatum | 2 | 1 |
| Aerococcus viridans | 1 | — |
| Globicatella species | 1 | — |
| Micrococcus luteus | 1 | — |
| Peptoniphilus harei | 2 | — |
| Anaerococcus prevotii | 1 | — |
| Finegoldia magna | 1 | — |
| Peptostrep. anaerobius | 1 | — |
| Escherichia coli | 3 | — |
| Klebsiella pneumoniae | 2 | 1 |
| Pseudomonas aeruginosa | 2 | 0 |
| Enterobacter cloacae complex | 2 | — |
| Morganella morganii | 2 | — |
| Proteus mirabilis | 1 | 1 |
| Raoultella planticola | 1 | 0 |
| Serratia marcescens | — | 0 |
| Escherichia hermannii | 1 | — |
| Pluralibacter gergoviae | 1 | — |
| Acinetobacter calcoaceticus | 1 | — |
| Bacteroides fragilis | 2 | — |
| Bacteroides thetaiotaomicron | 1 | — |
| Bacteroides vulgatus | 1 | — |
| Porphyromonas asaccharolytica | 2 | — |
| Prevotella melaninogenica | 2 | — |
| Prevotella disiens | 1 | — |
| Prevotella intermedia | 1 | — |
| Prevotella species | 1 | — |
Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).
| participants | Dalbavancin | Standard of Care |
|---|---|---|
| Staphylococcus aureus | 39 | 5 |
| Staphylococcus epidermidis | 6 | 2 |
| Staphylococcus haemolyticus | 3 | — |
| Staphylococcus pasteuri | 1 | — |
| Staphylococcus hominis | 1 | — |
| Staphylococcus simulans | 1 | — |
| Enterococcus faecalis | 7 | 0 |
| Enterococcus faecium | 1 | — |
| Streptococcus agalactiae | 1 | 1 |
| Streptococcus dysgalactiae | 1 | — |
| Streptococcus pyogenes | 1 | — |
| Corynebacterium striatum | 2 | 1 |
| Aerococcus viridans | 1 | — |
| Globicatella species | 1 | — |
| Micrococcus luteus | 1 | — |
| Peptoniphilus harei | 2 | — |
| Anaerococcus prevotii | 1 | — |
| Finegoldia magna | 1 | — |
| Peptostrep. anaerobius | 1 | — |
| Escherichia coli | 3 | — |
| Klebsiella pneumoniae | 2 | 1 |
| Pseudomonas aeruginosa | 2 | 1 |
| Enterobacter cloacae complex | 2 | — |
| Morganella morganii | 2 | — |
| Proteus mirabilis | 1 | 1 |
| Raoultella planticola | 1 | 1 |
| Serratia marcescens | — | 1 |
| Escherichia hermannii | 1 | — |
| Pluralibacter gergoviae | 1 | — |
| Acinetobacter calcoaceticus | 1 | — |
| Bacteroides fragilis | 2 | — |
| Bacteroides thetaiotaomicron | 1 | — |
| Bacteroides vulgatus | 1 | — |
| Porphyromonas asaccharolytica | 2 | — |
| Prevotella melaninogenica | 2 | — |
| Prevotella disiens | 1 | — |
| Prevotella intermedia | 1 | — |
| Prevotella species | 1 | — |
Collected over From Baseline (Day 0) to Day 365. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dalbavancin | 1/70 (1.4%) | 2/70 (2.9%) | 0/70 (0%) |
| Standard of Care | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Event | Dalbavancin | Standard of Care |
|---|---|---|
| Cardiac failure acuteCardiac disorders | 1/70 | 0/10 |
| Inflammation of woundInjury, poisoning and procedural complications | 1/70 | 0/10 |
Safety population included all intent-to-treat (ITT) participants who received any amount of randomized medication.
| Age, Continuous(years) | Dalbavancin | Standard of Care | Total |
|---|---|---|---|
| Mean | 49.2 ± 13.3 | 54.4 ± 15.3 | 49.8 ± 13.6 |
| Sex: Female, Male(Participants) | Dalbavancin | Standard of Care | Total |
|---|---|---|---|
| Female | 11 | 5 | 16 |
| Male | 59 | 5 | 64 |
| Race/Ethnicity, Customized(Participants) | Dalbavancin | Standard of Care | Total |
|---|---|---|---|
| White | 70 | 10 | 80 |
| Race/Ethnicity, Customized(Participants) | Dalbavancin | Standard of Care | Total |
|---|---|---|---|
| Not Hispanic or Latino | 70 | 10 | 80 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2016 to primary completion in Dec 2017, 20 months.
Results were first posted in Jan 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dalbavancin
Durata Therapeutics Inc., an affiliate of Allergan plc →